A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease

Figure 7

Mice were pretreated with DHB (100 mg/kg, intraperitoneally) 6 h prior to administration of either saline (Sal) or MPTP (20 mg/kg x2, 12 h apart). Animals were sacrificed 2 days later. (a) Levels of striatal IL-6 were measured using an ELISA kit from BD Biosciences. Each bar represents mean + SEM for 4 animals in each group. *𝑃<0.05 compared with the Sal group, **𝑃<0.01 compared with the MPTP-treated group. (b) DHB pretreatment decreases the mRNA levels of MPTP upregulated proinflammatory cytokines. *𝑃<0.05 compared with the Sal group, **𝑃<0.05 compared with the MPTP-treated group.

(a)

(b)